Article Per Year (5 Year)
p-Index From 2021 - 2026
0.659
P-Index
This Author published in this journals
All Journal Indonesian Journal of Rheumatology
Hidayat , Rudy
Unknown Affiliation
Medicine & Pharmacology

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
5 Year Survival of Systemic Lupus Erythematosus (SLE) Patients at RSCM and Predispose Factors: A Retrospective Cohort Study Hidayat , Rudy
Indonesian Journal of Rheumatology Vol. 17 No. 1 (2025): IJR VOL 17 No 1
Publisher : Indonesian Rheumatology Associantion

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background: Systemic Lupus Erythematosus (SLE) is an autoimmunerheumatic disease characterized by widespread inflammation involvingalmost all organ systems. This disease attacks young women with apeak incidence aged 15-40 years. The clinical manifestations of SLEvary depending on the organs involved. The risk of death in SLEpatients increases if it is not diagnosed and treated appropriately.Methods: This study is a retrospective cohort study using medicalrecord data from patients diagnosed with SLE for the first time in 20142019 at RSCM. Survival analysis was carried out on age, gender,hemolytic anemia, thrombocytopenia, NPSLE, high anti ds-DNA, lowC3 and C4, high dose glucocorticoids, lymphopenia, positive AntiCardiolipin Antibody (ACA), cardiovascular disease, and lupusnephritis. Multivariate analysis with cox regression was carried out.Results: There were 448 subjects studied. The five-year survival of SLEpatients at RSCM is 88%. Mean survival 56 months (95% CI : 55-57).In the multivariate analysis, it was found that NPSLE [p=0,000 ; HR3,595 (95%CI 1,932-6,688)], low C3 and C4 [p=0,004 ; HR 2,501(95%CI 1,330-4,701)], cardiovascular disease [p=0,018 ; HR 2,851(95%CI 1,198-6,787)], and hemolytic anemia [p=0,023 ; HR 2,106(95%CI 1,008-4,404)] had a significant effect on patient survival.Conclusion: The 5-year survival of SLE patients was 88% withneuropsychiatric lupus (NPSLE), low C3 dan C4, cardiovasculardisease, dan hemolytic anemia have a significant effect on the SLEsurvival patients at RSCM.
The The Prevalence and Factors Associated with Metabolic Syndrome in RheumatoidArthritis Patients Hidayat , Rudy
Indonesian Journal of Rheumatology Vol. 14 No. 2 (2022): IJR VOL 14 No 2
Publisher : Indonesian Rheumatology Associantion

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background: Rheumatoid arthritis (RA) is an independent risk factor ofcardiovascular disease (CVD), causing 30-50% mortality in RA patients.Metabolic syndrome is a combination of metabolic disorders that can bemanifested as central obesity, impaired blood pressure, or abnormalities ofcarbohydrate and lipid metabolism, which is closely associated with CVD inRA patients. The prevalence and factors associated with the incidence ofmetabolic syndrome in RA patients vary in previous studies. This studyaimed to determine the prevalence and factors associated with the incidenceof metabolic syndrome in RA patients at Cipto Mangunkusumo NationalCentral General Hospital, Jakarta. Methods: A total of 145 RA patients atthe Rheumatology Clinic of Cipto Mangunkusumo National Central GeneralHospital from October to December 2021 were included as research subjectsby consecutive sampling method. History taking about the disease anddemographic data, physical and anthropometric examination, andlaboratory tests were done on the patients. The prevalence of the metabolicsyndrome was determined using harmonization criteria. Statistical analysiswas performed to determine the association of the variables of age, smokinghabit, disease activity, duration of disease, glucocorticoid treatment, andmethotrexate treatment with metabolic syndrome in RA patients. Results:The prevalence of metabolic syndrome was 19.3% in RA patients with a mean age of 49.8 ± 11.6 years. The variables of gender, age, deformity, physical activity, extraarticular manifestation, smoking habit, disease activity,disease duration, glucocorticoid treatment, and methotrexate treatmentwere not statistically significant to the incidence of metabolic syndrome inRA patients. Conclusion: The prevalence of metabolic syndrome in RApatients in this study was 19.3%, and no variable was associated with theprevalence of metabolic syndrome. 
Characteristics and Treatment Responses of Rheumatoid Arthritis Patients at Dr.Cipto Mangunkusumo National General Hospital Hidayat , Rudy
Indonesian Journal of Rheumatology Vol. 15 No. 2 (2023): IJR VOL 15 No 2
Publisher : Indonesian Rheumatology Associantion

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Introduction. Rheumatoid arthritis (RA) is a chronic progressiveautoimmune rheumatic disease that primarily affects the joints. The goal ofRA treatment is to achieve remission or low disease activity, using a treatto-target approach. This study aims to explore the characteristics of RApatients and evaluate their treatment responses in Dr. CiptoMangunkusumo National General Hospital (RSCM). Methods. This crosssectionalstudyisconductedbycollectingdemographicandclinicaldata,as wellasinterviewingadultpatientsthathavebeendiagnosedwithRAatthe Rheumatology Clinic of RSCM and have been on disease-modifyingantirheumatic drugs (DMARD) treatment for a minimum of 6 months.Results. A total of 94 patients were included in this study. Subjects werepredominantly female (93.6%) and had no formal jobs (64.9%). A majority ofRA patients exhibited moderate disease activity (48.9%, based on DiseaseActivity Score-28 with erythrocyte sedimentation rate [DAS-28 ESR]), with arelatively high level of steroid use (86.2%). Notably, most patients startedDMARD treatment more than 2 years after the onset of symptoms (45.7%).The proportion of patients achieving therapy target (remission to low diseaseactivity) was 41.5%, with 13.8% attaining remission. Furthermore, HealthAssessment Quality (HAQ) scores were found to be significantly lower amongthe target-achieving group, indicating better quality of life. Conclusion.Therapy target was achieved in 41.5% of RA patients in RSCM, with 13.8%achieving remission. Further research can be conducted to evaluate factorswhich may affect treatment response among RA patients.   
Co-Authors